X

RET+ NSCLC

RET+ NSCLC

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer

The aim of this review is to explore recent knowledge on RET resistance in NSCLC in pre-clinic and in clinical settings and accordingly, the state-of-the-art in new drugs or combination of drugs de

Cancers
03/04/2021
ESMO Recommendations on the Standard Methods to Detect RET Fusions and Mutations in Daily Practice and Clinical Research

New selective RET inhibitors have activity and favorable toxicity profiles in RET-altered solid tumors.

Annals of Oncology
03/01/2021
Phase III Study of Selpercatinib Versus Chemotherapy ± Pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer

Selpercatinib demonstrates clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion positive NSCLC patients in a Phase I/II clinical tr

Future Oncology
11/05/2020

FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC

The FDA  approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive NSCLC, as detected by an FDA-approved test. 

The ASCO Post
09/08/2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39